Life Science Investor Mandates
(Feb. 21 - Feb. 27
)
|
|
|
|
|
with $500M RMB Fund Focuses Investments in Early-Stage Medtech/Digital Health Companies
|
|
Invests in Seed Stage, Technology-Based Early-Stage Companies in the Life Sciences Sector
|
|
Invests Up to $10M in Promising Therapeutics Discovery/Technology Platforms and Medical Devices
|
|
Seeks Joint Venture/Strategic Partnership Opportunities with Medtech Companies, with Strong Interest in Drug Delivery Devices & Technologies
|
|
|
 |
|
|
An interview with
Chuck Stetson, CEO, Stetson Family Office
- By
Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series
|
|
The Stetson Family Office has been active in driving global initiatives between two key investor groups: family offices that have desire and dollars to impact global health, and regional angel groups who have the ability to vet and recommend compelling early stage life science technologies. These alliances have the power to accelerate early stage investment across the silos of drugs, devices, diagnostics and digital health. There is a multitude of global early stage life science startups that are in need of early stage funding partners who can provide the capital to develop the next generation healthcare products. These next generation products will have a great impact on virtually everybody on the planet.
Dennis:
Chuck, what exactly is the Global Family Office BioForum (GFOB)? How many Family Offices participate and how many cities throughout the world?
Chuck:I created and launched the entity Global BioForum because like my own family office, I discovered there were other family offices that are genuinely interested in philanthropy and social impact investing in healthcare, but finding and vetting the technology assets proved to be a challenge for them because of limited staff. To meet the challenge I created a strategy to match up regional angel networks with up to 40 members vetting each deal with regional family offices within the early stage life science arena...
|
 |
 |
|
By Lucy Parkinson, VP of Investor Research, LSN
 RESI Europe's two tracks of investor panel content will feature panel discussions that aim to inform entrepreneurs on how raising capital works in their vertical, and how major investor categories such as Family Offices, Angels, Seed Funds, and Big Pharma source and assess new healthcare technologies. With dozens of speakers coming from top firms, LSN would like to introduce you to some of the luminaries who will be appearing at RESI to provide their advice and expertise to attending entrepreneurs.
- Chuck Steston, Stetson Family Office, Family Offices & Angels
- Florence dal Degan, Novo Nordisk, Big Pharma
- Philipp Rittershaus, High-Tech Gründerfonds, Seed Funds
- Marco Boorsma, Forbion, Early Stage Therapeutics
- Roel Bulthuis, INKEF Capital, Early Stage Therapeutics
|
|
|
By Nono Hu, Director of Marketing, LSN
 The Redefining Early Stage Investments (RESI) Conference makes its return to the BIO International Convention on June 3rd in Philadelphia, PA. This is the third time LSN has held a RESI Conference during BIO week, which promises to bring more than 16,000 life science executives to Philly.
RESI specializes in early stage investor partnering and provides an opportunity for early-stage life science companies across Drugs, Devices, Diagnostics and Digital Health to meet one on one with investors and strategic partners from around the globe. At RESI, entrepreneurs can create relationships that will potentially lead to receiving investment. RESI Philadelphia 2019 conference also invites the earliest stage companies from the discovery stage through venture stage: companies seeking grants, seed rounds, angel investments, Series A, and Series B funding...
|
|
Created & Produced by
|
 |
|
|
|
